IM-6EXX

IM-6EXX is an experimental therapeutic candidate being developed by ITabMed for the treatment of solid tumors. While specific molecular targets for this candidate have not been publicly disclosed in detail, it is part of ITabMed's pipeline which utilizes their proprietary iTAb™ (Immune-Targeting Antibody) bispecific antibody platform. This platform is designed to create T-cell engaging bispecific antibodies that typically feature a T-cell binding domain (such as CD3) and a tumor-associated antigen binding domain to facilitate the targeted destruction of cancer cells. Based on the company's technology focus, IM-6EXX is likely a bispecific antibody or T-cell engager intended to redirect the immune system against solid tumor targets.